ATR and cancer: In our analysis, T‐ALL cell lines showed increased sensitivity to inhibitors of ATR (AZD6738, ceralasertib), CHK1/2 (AZD7762 and MK‐8776), and Wee1 (AZD1775, adavosertib) as measured by a reduced IC50 compared with other non‐T‐cell cancer cells (Fig 7A–C).